|
Different approaches to routine screening with tuberculin skin test and QuantiFERON®TB Gold |
||||
| Screening programme approach |
Referral criteria |
Proportion (%) referred for treatment |
Proportion (%) LTBI* cases detected (detection rate) |
Proportion (%) non-infected referred for treatment (false positive rate) |
|
|
||||
| Only TST |
TST ≥ 6 mm |
50 |
89 |
42 |
| TST ≥ 10 mm |
34 |
75 |
27 |
|
| TST ≥ 15 mm |
15 |
47 |
0 |
|
| Only QFT |
QFT positive |
29 |
88 |
0 |
| Two step (first TST, then QFT) |
TST ≥ 6 mm and QFT positive, or TST ≥15 mm |
29 |
89 |
0 |
| TST ≥ 10 mm and QFT positive or TST ≥ 15 mm |
25 |
75 |
0 |
|
| TST ≥ 15 mm (with or without QFT positives afterwards) |
15 |
47 |
0 |
|
|
*Latent infection is defined as either having a positive QuantiFERON(R)TB Gold test (264 participants) or a tuberculin skin test ≥15 mm and a negative QuantiFERON(R)TB Gold test (37 participants). Effect on screening based on identification of 301 cases of latent tuberculosis infection among 912 newly arrived asylum seekers in Norway Sept. 19. 2005 – June 12.2006 | ||||
Winje et al. BMC Infectious Diseases 2008 8:65 doi:10.1186/1471-2334-8-65 |
||||